From an executive order to lower drug prices to GLP-1 drug comparisons and a link between Parkinson’s disease and golf courses, it was a busy industry news week.
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
Michael Bollong and his team discovered a way to restore lung stem cells’ regenerative capacity and a potential drug for idiopathic pulmonary fibrosis.
No pharmaceutical treatments exist for addictions to drugs like cocaine or cannabis. Now, scientists are engineering gene therapies, immunotherapies, and more.